Wee1 Inhibitor

Wee1 Inhibitors (29):

Cat. No.	Product Name	Effect	Purity

HY-10993

Adavosertib	Inhibitor	99.96%
Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC₅₀ of 5.2 nM.

HY-132295

Azenosertib	Inhibitor	99.96%
Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC₅₀=3.9 nM). Azenosertib exhibits antitumor activity.

HY-13925

PD0166285	Inhibitor	99.46%
PD0166285, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC₅₀ values of 24 and 72 nM, respectively. PD0166285 exhibits an IC₅₀ of 3.433 μM for Chk1.

HY-147054

Zedoresertib	Inhibitor	99.85%
Zedoresertib (Debio 0123) is a potent WEE1 inhibitor with an IC₅₀ value of 0.8 nM. Zedoresertib inhibits phospho-CDC2. Zedoresertib abrogates the G2 check point, increasing sensitivity to DNA damaging agents in cancer cells. Zedoresertib can be used for researching anticancer.

HY-183278

APO-50815	Inhibitor
APO-50815 is a WEE1 kinase inhibitor with a human IC₅₀ of 9 nM. APO-50815 induces DNA damage, replication stress, S-phase cell accumulation, and apoptosis. APO-50815 can be used for the research of metastatic colorectal cancer.

HY-176957

PKMYT1-IN-11	Inhibitor
PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC₅₀ of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer.

HY-182433

CJM061	Inhibitor
CJM061 is a WEE1 kinase inhibitor with a target IC₅₀ of 2.8 nM. CJM061 acts as a sensitizer and exhibits synergistic effects with Cisplatin (HY-17394) in medulloblastoma cells. CJM061 can be used for the research of medulloblastoma.

HY-N0819

Raddeanin A	Inhibitor	98.55%
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

HY-147312

GSK-1520489A	Inhibitor	99.83%
GSK-1520489A is a PKMYT1 (active protein kinase) inhibitor (IC₅₀=115 nM, K_i=10.94 nM).

HY-108343

WEE1-IN-4	Inhibitor	99.70%
WEE1-IN-4 (compound 15) is a pyrrolocarbazole-1,3(2H,6H)-dione derivative and Wee1 kinase inhibitor with an IC₅₀ value of 11 nM.WEE1-IN-4 can be used for the research of cancer.

HY-103029

Bosutinib isomer	Inhibitor	99.62%
Bosutinib isomer is a ligand or inhibitor with high binding affinity for both Wee1 and Wee2, with K_d values of 43.7 ± 10.0 and 4.7 ± 2.3 nM, respectively.

HY-138239

WEE1-IN-3	Inhibitor	98.64%
WEE1-IN-3 is a potent Wee1 kinase inhibitor with an IC₅₀ of <10 nM. WEE1-IN-3 has anticancer activities.

HY-161880

WEE1-IN-10	Inhibitor	99.32%
WEE1-IN-10 (compound 77) is a Wee1 kinase inhibitor. WEE1-IN-10 shows inhibitory activity on LOVO cell growth, with an IC₅₀ of 0.524 μM. WEE1-IN-10 can be used for the research of diseases caused by abnormal activity of Wee1.

HY-163697

WEE1-IN-7	Inhibitor	99.70%
WEE1-IN-7 (compound 12h) is a potent and orally activeWEE1 inhibitor with an IC₅₀ value of 2.1 nM. WEE1-IN-7 induces apoptosis and cell cycle arrest at the S phase. WEE1-IN-7 shows antitumor activity.

HY-10993R

Adavosertib (Standard)	Inhibitor
Adavosertib (Standard) is the analytical standard of Adavosertib. This product is intended for research and analytical applications. Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC₅₀ of 5.2 nM.

HY-178190

WEE1-IN-13	Inhibitor
WEE1-IN-13 (Compound 10) is a highly selective WEE1 kinase inhibitor (IC₅₀=0.7 nM). WEE1-IN-13 abrogates the G2/M checkpoint and induces tumor cell apoptosis. WEE1-IN-13 is promising for research of solid tumors (e.g., non-small cell lung cancer, ovarian cancer).

HY-178150

WEE1-IN-14	Inhibitor
WEE1-IN-14 (Compound 14) is a selective WEE1 inhibitor (IC₅₀: 0.5 nM in L-RB-FEP calculations, 1.0 nM in ADP-Glo kinase assay). Inhibition of Wee1 in cancer cells disrupts the G2-M checkpoint, removes the regulatory controls on the cell cycle, and leads to early onset of mitotic failure followed by apoptosis of tumor cells. Therefore, WEE1-IN-14 is a useful tool for studying cancer biology.

HY-174448

WEE1-IN-12	Inhibitor
WEE1-IN-12 (Compound 87) is a Wee1 kinase inhibitor with an IC₅₀ of 2.0 nM. WEE1-IN-12 can inhibit the proliferation of HT29 cells (IC₅₀: 1.07 μM), and when used in combination with Gemcitabine (HY-17026), the effect is better (IC₅₀: 0.34 μM). WEE1-IN-12 can be used in the research of tumors such as colon cancer.

HY-133703A

i-AZD1775 TFA	Inhibitor
i-AZD1775 (TFA) is an immobilizable analogue of AZD1775. i-AZD1775 (TFA) retains the ability to inhibit WEE1 in vitro. i-AZD1775 (TFA) can be studied in anticancer research.

HY-161879

WEE1-IN-9	Inhibitor
WEE1-IN-9 (Compound 1) is a Wee1 inhibitor that can be used in cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.